Allergan to Acquire Elastagen's Next Generation Injectable Portfolio for $95m

Allergan Plc, a $15.9b provider of medical aesthetics, biosimilars, and over-the-counter pharmaceutical products will acquire Elastagen Pty Ltd., a provider of advanced tissue repair platform based on tropoelastin (gives tissue its elasticity) for $95m. The acquisition adds proprietary injectable products to Allergan's existing portfolio. Elastagen’s technology is based on human tropoelastin, the precursor of elastin which is a key component of youthful skin. Its products is identical to that present in human tissue and can treat acne scars, stretch marks. It can also repair skin and surgical wounds. Deal value -- $95m.

Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers